Abstracts tagged "Epidemiologic methods"

Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Alaina Davis ², Marisa Klein-Gitelman ³, Zuleyha Cidav ⁴, David Mandell ⁵ and Andrea Knight ⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, ³Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶SickKids Research Institute, Toronto, Canada
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis
Cal Robinson ¹, Rahul Chanchlani ¹, Megan Schlorff ¹, Francis Lao ¹, Tapas Mondal ¹, Catherine Demers ¹, Elizabeth Darling ¹, Sandeep Brar ², Rulan Parekh ³, Hsien Seow ¹, Eric Benchimol ⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²University of California, San Fransisco, ³University of Toronto, Toronto, Canada, ⁴University of Ottawa, Ottawa, Canada
Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
Abstract Number: 103 • 2020 Pediatric Rheumatology Symposium
Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abdulrahman Alkanhal¹, Joseph , Saunders ², Fajer Altammar ³, Adam Huber ⁴, Andrew Lynk ², Alison MacLeod ⁵, Oliva Ortiz-Alvarez ⁶, Meighan Adams ², Suzanne Ramsey ⁷, Elizabeth Stringer ⁷, Andrew Warren ² and Bianca Lang ⁸, ¹University of Alberta, Edmonton, Alberta, Canada, ²Dalhousie University, Halifax, Canada, ³Mcmaster University, Hamilton, Canada, ⁴IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁵Annapolis Valley Health, Kentville, Canada, ⁶St Martha's Regional Hospital, Antigonish, Canada, ⁷IWK Health Centre, Halifax, Canada, ⁸Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: Kawasaki Disease (KD), a systemic vasculitis of unknown etiology, is now the leading cause of acquired heart disease in children in North America. Its…
Abstract Number: 1278 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States
Patompong Ungprasert¹, Wisit Cheungpasitporn ², Charat Thongprayoon ³, Karn Wijarnpreecha ⁴ and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²University of Mississippi Medical Center, Jackson, MS, ³Mayo Clinic Rochester, Rochester, MN, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM), collectively known as idiopathic inflammatory myositis (IIM), are autoimmune disorders characterized by inflammation of skeletal muscle, especially in the…
Abstract Number: 1682 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Granulomatosis with polyangiitis (GPA, formerly known and Wegener’s granulomatosis) is a major subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by granulomatous inflammation of…
Abstract Number: 1685 • 2019 ACR/ARP Annual Meeting
Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Due to the rarity of polyarteritis nodosa (PAN), no study has ever investigated inpatient characteristics, healthcare utilization and frequency of comorbidities of patients with…
Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting
Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Daniel Solomon¹, Robert Glynn ², Elizabeth Karlson ³, Fengxin Lu ³, Cassandra Corrigan ³, Joshua Colls ³, Chang Xu ³, Jean MacFadyen ³, Medha Barbhaiya ⁴, Nancy Berliner ³, Paul Dellaripa ³, Brendan Everett ³, Sara Hammond ³, Meredith Murray ³, Deepak Rao ³, Susan Ritter ⁵, Anna Rutherford ⁵, Jeffrey Sparks ³, Jacklyn Stratton ⁵, Dong Suh ³, Sara K. Tedeschi ⁶, Kathleen Vanni ³, Nina Paynter ⁵ and Paul Ridker ⁵, ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Harvard Medical School - Boston, MA, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
Abstract Number: 2313 • 2019 ACR/ARP Annual Meeting
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam ² and Ben Ponvilawan ², ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mahidol University, Bangkok, Thailand
Background/Purpose: Patients with chronic autoimmune diseases may have a higher risk of psychiatric illness as a result of chronic neuro-inflammation and immune dysregulation. The current…
Abstract Number: 2715 • 2019 ACR/ARP Annual Meeting
Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset
Ruth Costello¹, Janet McDonagh ², Will Dixon ¹, Kimme Hyrich ² and Jenny Humphreys ¹, ¹Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ²Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common childhood onset inflammatory arthritis. The last estimates of incidence of this disease in the United Kingdom…
Abstract Number: 2824 • 2019 ACR/ARP Annual Meeting
Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)
Navraj Nagra¹, Danielle Robinson ², Antonella Delmestri ¹, Stephanie Dakin ¹, Sarah Snelling ¹, Andrew Carr ¹ and Daniel Prieto-Alhambra ¹, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: The microbiome and specific bacterial triggers have been hypothesised to be involved in the pathogenesis of Rheumatoid Arthritis (RA) and RA flares. Antibiotic usage…
Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Jeffrey Sparks¹, Susan Malspeis ¹, Jill Hahn ², Andrea Roberts ², Laura Kubzansky ² and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…
Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 179 • 2019 ACR/ARP Annual Meeting
The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Sofia Pazmino ¹, Veerle Stouten ¹, Patrick Verschueren ², Pavlos Mamouris ¹, Rene Westhovens ³, Kurt De Vlam ², Delphine Bertrand ¹, Kristien Van der Elst ², Bert Vaes ¹ and Diederik De Cock¹, ¹KU Leuven, Leuven, Belgium, ²University Hospital Leuven, Leuven, Belgium, ³University Hospitals, Leuven, Belgium
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…
Abstract Number: 181 • 2019 ACR/ARP Annual Meeting
Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population
Jon Giles¹, Lee Simon ², Janet Pope ³, Jim Paik ⁴, Michael Grabner ⁵, Amanda Quebe ⁶, Carol Gaich ⁶, Claudia Salinas ⁶ and Jeffrey Curtis ⁷, ¹Division of Rheumatology, Columbia University, New York, NY, ²SDG LLC, Cambridge, ³Western University, London, ON, Canada, ⁴Eli Lilly & Company, Indianapolis, IN, ⁵HealthCore, Inc., Wilmington, DE, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Clinical management of rheumatoid arthritis (RA) must consider patient renal function, particularly for medications that rely on renal clearance and require dose adjustment or…
Abstract Number: 183 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Data-driven principal component (PC) and cluster analysis has the potential to identify previously unknown patient subgroups within a rheumatoid arthritis (RA) registry to establish…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].